New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:16 EDTHTZ, BTU, HDSN, SEAC, CMTL, NVAX, RALY, GWPH, ANGI, DMNDOn The Fly: Pre-market Movers
HIGHER: Angie's List (ANGI), up 7% after shares upgraded at BofA Merrill Lynch... GW Pharmaceuticals (GWPH), up 7.5% after receiving Fast Track designation for Epidiolex... Comtech (CMTL), up 6% after Q3 earnings beat, raised FY14 outlook. LOWER: Hertz (HTZ), down 10% after warning its Q1 results are "likely to be below consensus," disclosing that errors were identified during its preparation of its financial statements and that certain statements must be restated... Rally Software (RALY), down 23% after downgraded at William Blair, Deutsche Bank and Needham following the company's Q1 results... Novavax (NVAX), down 7.5% after filing to sell $100M of common stock... SeaChange (SEAC), down 10% after reporting disappointing earnings, guidance... Diamond Foods (DMND), down 7.5% after reporting lower than expected Q3 results... Hudson Technologies (HDSN), down 6.5% after 6M share spot secondary offering of shares priced at $2.50... Peabody (BTU), down 2% after shares downgraded at Goldman.
News For HTZ;ANGI;GWPH;RALY;NVAX;CMTL;SEAC;HDSN;BTU;DMND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
05:26 EDTGWPHGW Pharmaceuticals Epidiolex receives orphan designation from EMA
GW Pharmaceuticals announced that the European Medicines Agency, or EMA, has granted orphan designation to GW's investigational product Epidiolex in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. In addition to this orphan designation by the EMA, GW has been granted Fast Track designation by the FDA for Epidiolex in the treatment of Dravet syndrome as well as orphan designations in both Dravet syndrome and Lennox-Gastaut syndrome, or LGS. GW is about to commence a full clinical development program for Epidiolex in the treatment of both Dravet syndrome and LGS, working with leading pediatric epilepsy specialists across the U.S. The first Phase 2/3 clinical trial is due to commence in the coming weeks.
October 21, 2014
14:09 EDTHTZThird Point discloses new positions in eBay, Alibaba, exit from Sony
In its Q3 investor letter, Third Point says it established a "significant" position in eBay (EBAY). Dan Loeb's hedge fund also revealed it has established a significant direct investment in Alibaba (BABA) shares now that the company is public. Third Point also said it is now one of Amgen's (AMGN) largest shareholders. During the quarter, Third Point exited its position in Sony (SNE) and reduced or exited other positions, including AIG (AIG), Hertz (HTZ) and Softbank (SFTBF), the firm stated in its letter. PRICE ACTION: Following the disclosures in the Third Point letter, Amgen is up 4%, eBay is up 2.3% and Alibaba is up 3.8%, while Sony shares trading in New York are down nearly 1%.
13:00 EDTCMTLComtech awarded $2.3M advanced VSAT and Premium Services Order in Asia
Subscribe for More Information
11:02 EDTHTZHertz, United Airlines upgrade partnership
Subscribe for More Information
08:12 EDTHTZNissan selects Hertz as exclusive mobility partner
Subscribe for More Information
07:20 EDTSEACSeaChange announces retirement of CEO Raghu Rau, Jay Samit named CEO
Subscribe for More Information
07:03 EDTSEACSeaChange appoints Jay Samit as CEO
SeaChange announced that the board has unanimously appointed Jay Samit as CEO effective immediately. Samit will also become a member of the Board. Samit succeeds SeaChange's current CEO Raghu Rau. Samit was most recently president at ooVoo.
October 20, 2014
08:58 EDTHTZJana Partners reports 7% stake in Hertz, says may engage in talks
Subscribe for More Information
08:54 EDTHDSNEPA ruling substantially better than expected for Hudson, says Roth Capital
Subscribe for More Information
08:10 EDTBTUPeabody sees FY14 adjusted EPS ($1.48)-($1.38), consensus ($1.46)
Targets reflect lower seaborne thermal coal pricing and reduced production at the Wilpinjong Mine as strong year-to-date performance is expected to result in the mine reaching annual permit levels before year end. Expects total sales of 245 to 255 million tons, including U.S. sales of 185 to 190 million tons and Australian sales of 36 to 38 million tons; U.S. costs per ton 1 to 3 percent below 2013 levels on cost containment efforts. U.S. revenues per ton improved to 2 to 4 percent below 2013 levels on higher realized price per ton; and Australian costs that have been lowered to approximately $70 per ton, as a result of successful cost reduction initiatives and operating performance.
08:08 EDTBTUPeabody cuts FY14 CapEx to $200M-$220M
Subscribe for More Information
08:08 EDTBTUPeabody seeing favorable industry indicators over Chinese coal imports
Subscribe for More Information
08:07 EDTBTUPeabody reports Q3 adjusted EPS (59c), consensus (66c)
Subscribe for More Information
07:16 EDTANGIAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 17, 2014
14:18 EDTHDSNHudson Technologies resumes, up 28% after comments on EPA final rule on R-22
Subscribe for More Information
13:53 EDTHDSNHudson Technologies halted, to resume trading at 2:15 pm ET
Hudson Technologies shares were halted, pending news, subsequent to which the company announced that the EPA signed the final rule pertaining to allowances for virgin production of HCFCs, primarily R-22, for 2015 through 2019. Hudson Chairman and CEO Kevin Zugibe stated in the press release related to the news: "The EPA’s final rule provides much needed clarity to our industry and delivers a significantly more aggressive step down approach for the phase-out of R-22, which we have consistently stated is the best method to achieve an orderly phase-out of virgin R-22 and for the establishment of reclamation as the principal, and ultimately the sole source of supply of R-22...As one of the leading reclaimers in the marketplace, the R-22 phase-out provides a significant, long-term opportunity for Hudson.” Quotation will resume at 2:10 pm ET, according to Nasdaq.
13:46 EDTHDSNHudson Technologies reports EPA finale rule on allowances for 2015-2019
Subscribe for More Information
13:45 EDTHDSNHudson Technologies trading halted, pending news
08:28 EDTNVAXNovavax management to meet with JPMorgan
Subscribe for More Information
08:04 EDTBTUPeabody volatility elevated into Q3 and outlook
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use